MiR-494 inhibits tumor progression by targeting LETMD1 in cervical cancer
LI Xin1,2,DONG Lixin2,YANG Sen2, CAO Liyan2,MAO Yu2,FU Zhanzhao2,DONG Siqi3
1.Chengde Medical College, Chengde 067000,China; 2. Department of Oncology, 3.Department of Orthopaedics, the First Hospital of Qinhuangdao,Qinhuangdao 066000, China
Abstract：Objective To explore the role of LETMD1-targeting miR-494 in the progression of cervical cancer.Methods miRNA-494 mRNA and LETMD1 protein expressions in clinical samples were determined to confirm the effects on cell proliferation, invasion and migration.Results The expression of miR-494 in tissue samples of cervical cancer was significantly decreased, and its expression level was negatively correlated with the FIGO stage (P<0.05). LETMD1 was identified as a target gene of miR-494 in cervical cancer cells by dual-luciferase assay. Functional experiments demonstrated that miR-494 could inhibit the cell proliferation via the negative regulation of LETMD1 expression.Conclusions Our findings provide important evidence for the role of miR-494 as a tumor suppressor in cervical cancer via the inhibition of LETMD1 expression.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015,136(5):E359-386.
[2]
Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015,65(2):87-108.
[3]
Ko J, Lee Y H, Hwang S Y, et al. Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization[J]. Oncogene, 2003,22(30):4679-4689.
[4]
Peralta Z O, Deas J, Meneses A A, et al. Relevance of miR-21 in regulation of tumor suppressor gene PTEN in human cervical cancer cells[J]. BMC Cancer, 2016,16:215.
Ha S A, Lee Y S, Shin S M, et al. Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status[J]. BMC Cancer, 2009,9:51.
[7]
Xu Z, Zhang Y, Jiang J, et al. Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells[J]. BMC Cancer, 2010,10:161.
[8]
Zhang J L, Liu X Z, Wang P Y, et al. Targeting HCCR expression resensitizes gastric cancer cells to chemotherapy via down-regulating the activation of STAT3[J]. Sci Rep, 2016,6:24196.
[9]
Zhang G, Ha S A, Kim H K, et al. Combined analysis of AFP and HCCR-1 as an useful serological marker for small hepatocellular carcinoma: a prospective cohort study[J]. Dis Markers, 2012,32(4):265-271.
Wezel A, Welten S M, Razawy W, et al. Inhibition of MicroRNA-494 reduces carotid artery atherosclerotic lesion development and increases plaque stability[J]. Ann Surg, 2015,262(5):841-848.
[12]
Zhang Y, Guo L, Li Y, et al. MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer[J]. Mol Cancer, 2018,17(1):12.
[13]
Zhang J, Wang T, Zhang Y, et al. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients[J]. Cancer Biomark, 2018,21(4):763-768.
[14]
Ma Y, Li G, Hu J, et al. MicroRNA-494 regulates Gli3 expression and inhibits pancreatic cancer cells growth and migration[J]. J Cell Biochem, 2018,119(7):5324-5331.
[15]
Zhan M N, Yu X T, Tang J, et al. MicroRNA-494 inhibits breast cancer progression by directly targeting PAK1[J]. Cell Death Dis, 2017,8(1):2529.
[16]
Chen B, Hou Z, Li C, et al. MiRNA-494 inhibits metastasis of cervical cancer through pttg1[J]. Tumour Biol, 2015,36(9):7143-7149.
Cheng L, Kong B, Zhao Y, et al. miR-494 inhibits cervical cancer cell proliferation through upregulation of SOCS6 expression[J]. Oncol Lett, 2018,15(3):3075-3080.
2019, Vol. 30 
